Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the ...
Pharmabiz

Alto Neuroscience receives US patent for ALTO-207; strengthens IP portfolio for patients with treatment-resistant depression

Alto Neuroscience receives US patent for ALTO-207; strengthens IP portfolio for patients with treatment-resistant depression: Mountain View, California Saturday, January 17, 2026, ...

Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
News Medical

Brain serotonin levels linked to sexual side effects from antidepressants

Researchers have discovered that the ability to have an erection or to orgasm is related to the levels of serotonin in the brain, but this relation only applies to depressed patients taking SSRI ...